RYBREVANT FASPRO™ Receives FDA Approval for First-Line EGFR-Mutated NSCLC
December 26, 2025
Free CME credits
Both our subscription plans include Free CME/CPD AMA PRA Category 1 credits.
Brand Name :
Minocin
(United States) [Available] ,Emrosi
(United States) [Available]Synonyms :
minocycline
Class :
Tetracyclines
Brand Name :
Minocin
(United States) [Available] ,Emrosi
(United States) [Available]Synonyms :
minocycline
Class :
Tetracyclines
Dosage Forms & Strengths
Tablet or Capsule
50mg
75mg
100mg
Tablet- extended release
45mg
55mg
65mg
80mg
90mg
105mg
135mg
initial dose:
200
mg
Intravenous (IV)
followed by 100 mg IV for every 12hrs maximum dose: 400 mg IV per day
for 45-49 kg weight 45 mg orally once a day
for 50-59 kg weight 55 mg orally once a day
for 60-71 kg weight 65 mg orally once a day
for 72-84 kg weight 80 mg orally once a day
for 85-96 kg weight 90 mg orally once a day
for 97-110 kg weight 105 mg orally once a day
for 111-125 kg weight 115 mg orally once a day
for 126-136 kg weight 135 mg orally once a day
maximum duration of the treatment is 12 weeks
200 mg IV given initially, followed by 100 mg IV every 12hrs
maximum dose given per day is 400 mg
Meningococcal Meningitis Prophylaxis:
100 mg given orally every 12hrs for about five days
200 mg IV given initially, followed by 100 mg IV every 12hrs
maximum dose given per day is 400 mg
200 mg given initially, followed by 100 mg orally every 12hrs
100 to 200 mg initially followed by 50 mg orally four times a day for an alternative regimen
100 mg orally every 12hrs for five days for urethritis in men
200 mg initially followed by 100 mg orally every 12hrs for at least four days for infections other than urethritis and anorectal infections in men
Dosage Forms & Strengths
Tablet or capsule
50mg
75mg
100mg
Tablet-extended release
45mg
55mg
65mg
80mg
90mg
105mg
135mg
Age: >12years
Extended-release formulations:
for 45-49 kg weight 45 mg orally once a day
for 50-59 kg weight 55 mg orally once a day
for 60-71 kg weight 65 mg orally once a day
for 72-84 kg weight 80 mg orally once a day
for 85-96 kg weight 90 mg orally once a day
for 97-110 kg weight 105 mg orally once a day
for 111-125 kg weight 115 mg orally once a day
for 126-136 kg weight 135 mg orally once a day
maximum duration of treatment is 12 weeks
For > 8 years:
4 mg per kg given orally or IV initially followed by 2 mg per kg orally or IV every 12hrs
Maximum dose 200 mg per dose initially followed by 200 mg per day
When both drugs are combined, there may be an increased intracranial pressure
When both drugs are combined, there may be an increased intracranial pressure
may diminish the absorption when combined with tetracyclines
may diminish the absorption when combined with tetracyclines
may diminish the absorption when combined with tetracyclines
may diminish the absorption when combined with tetracyclines
may diminish the absorption when combined with tetracyclines
aluminum hydroxide/magnesium carbonate
may decrease the serum concentration of antacids
may diminish the absorption when combined with tetracyclines
may diminish the absorption when combined with tetracyclines
may diminish the absorption when combined with tetracyclines
may diminish the absorption when combined with tetracyclines
may diminish the absorption when combined with tetracyclines
When both drugs are combined, there may be a decrease in levels of minocycline by inhibition of GI absorption
When both drugs are combined, there may be an increased risk or severity of adverse effects
When both drugs are combined, there may be an increased risk or severity of adverse effects
When both drugs are combined, there may be a decreased therapeutic effect of the vaccine
when both drugs are combined, there may be a decrease in levels of minocycline by inhibition of GI absorption
When both drugs are combined, there may be a decrease in levels of the other by inhibition of GI absorption
When both drugs are combined, there may be a decrease in levels of the other by inhibition of GI absorption
When both drugs are combined, there may be a decrease in levels of the other by inhibition of GI absorption
When both drugs are combined, there may be a decrease in levels of the other by inhibition of GI absorption
bismuth subsalicylate reduces the levels of minocycline by inhibiting gastrointestinal absorption
lansoprazole amoxicillin and clarithromycin
when amoxicillin combines with minocycline it decreases the effects of action of drug by antagonism effect
amoxicillin and clavulanate potassium
when amoxicillin combines with minocycline it decreases the effects of action of drug by antagonism effect
omeprazole amoxicillin and clarithromycin
when both drugs are combined, there may be a decreased effect of the drug's action by antagonism effect
when both drugs are combined, there may be a decreased effect of the drug's action by antagonism effect
may diminish the absorption of magnesium salts
aluminum hydroxide/magnesium hydroxide
may diminish the absorption of Antacids
When both drugs are combined, there may be an increased risk or severity of adverse effects
When both drugs are combined, there may be an increased risk or severity of adverse effects
When both drugs are combined, there may be an increased risk or severity of adverse effects
When both drugs are combined, there may be an increased risk or severity of adverse effects
When both drugs are combined, there may be an increased risk or severity of adverse effects
When both drugs are combined, there may be an increased risk or severity of adverse effects
When both drugs are combined, there may be an increased risk or severity of adverse effects
When both drugs are combined, there may be a decreased effect of conjugated estrogens by altering intestinal flora
it increases the effect of CNS depressants
it increases the effect of CNS depressants
it increases the effect of CNS depressants
it increases the effect of CNS depressants
it increases the effect of CNS depressants
may increase the CNS depressant effect
may increase the CNS depressant effect
may increase the CNS depressant effect
may increase the CNS depressant effect
may increase the CNS depressant effect
may increase the CNS depressant effect
may increase the CNS depressant effect
may increase the CNS depressant effect
it increases the effect of neuromuscular blockage of neuromuscular-blocking agents
it increases the effect of neuromuscular blockage of neuromuscular-blocking agents
it increases the effect of neuromuscular blockage of neuromuscular-blocking agents
it increases the effect of neuromuscular blockage of neuromuscular-blocking agents
it increases the effect of neuromuscular blockage of neuromuscular-blocking agents
it increases the effect of CNS depressants
it increases the effect of CNS depressants
it increases the effect of CNS depressants
may have an increased neuromuscular-blocking effect when combined with neuromuscular-blocking agents
may have an increased neuromuscular-blocking effect when combined with neuromuscular-blocking agents
may have an increased neuromuscular-blocking effect when combined with neuromuscular-blocking agents
may have an increased neuromuscular-blocking effect when combined with neuromuscular-blocking agents
may have an increased neuromuscular-blocking effect when combined with neuromuscular-blocking agents
may increase the risk of adverse effects
may increase the risk of adverse effects
may increase the risk of adverse effects
may increase the risk of adverse effects
may increase the risk of adverse effects
may enhance the neuromuscular-blocking effect
may enhance the neuromuscular-blocking effect
may enhance the neuromuscular-blocking effect
may enhance the neuromuscular-blocking effect
may enhance the neuromuscular-blocking effect
may enhance the neuromuscular-blocking effect
may enhance the neuromuscular-blocking effect
may enhance the neuromuscular-blocking effect
may enhance the neuromuscular-blocking effect
may enhance the neuromuscular-blocking effect
may enhance the neuromuscular-blocking effect
may enhance the adverse/toxic effect
may enhance the adverse/toxic effect
may enhance the adverse/toxic effect
may enhance the adverse/toxic effect
may enhance the adverse/toxic effect
ay enhance the anticoagulant effect
ay enhance the anticoagulant effect
ay enhance the anticoagulant effect
ay enhance the anticoagulant effect
ay enhance the anticoagulant effect
minocycline (Systemic): they may increase the CNS depressant effect of CNS Depressants
minocycline (Systemic): they may increase the CNS depressant effect of CNS Depressants
minocycline (Systemic): they may increase the CNS depressant effect of CNS Depressants
They may diminish the absorption when combined with bile acid sequestrants
They may diminish the absorption when combined with bile acid sequestrants
trimagnesium citrate anhydrous
The presence of trimagnesium citrate anhydrous inhibits the gastrointestinal absorption of minocycline, resulting in reduced levels
it may diminish the excretion rate when combined with tetracyclines, resulting in an enhanced serum level
may have an increased neuromuscular-blocking effect when combined with neuromuscular-blocking agents
may diminish the effect of each other when combined
may diminish the effect of each other when combined
may diminish the effect of each other when combined
may diminish the effect of each other when combined
sodium picosulfate, citric acid, and magnesium oxide
may diminish the effect of each other when combined
may decrease the therapeutic effect when combined with penicillins
amoxicillin and clavulanate potassium
may decrease the therapeutic effect when combined with penicillins
may decrease the therapeutic effect when combined with penicillins
may decrease the therapeutic effect when combined with penicillins
may decrease the therapeutic effect when combined with penicillins
piperacillin decreases the effectiveness of minocycline by antagonism.
When bacampicillin combines with minocycline, the effect and action of bacampicillin decreases.
When penicillin G benzathine combines with minocycline, the action and effectiveness of penicillin G benzathine decreases.
when both drugs are combined, there may be a reduced effect of ceftriaxone by pharmacodynamic antagonism
The interaction may depress the therapeutic efficacy of tetracyclines
may increase the CNS depressant effect
may increase the CNS depressant effect
may increase the CNS depressant of CNS depressants
may increase the CNS depressant effect of CNS depressants
may increase the toxic effect of anticholinergic agents
may reduce the rate of absorption of tetracyclines
may reduce the rate of absorption of tetracyclines
may reduce the rate of absorption of tetracyclines
may reduce the rate of absorption of tetracyclines
may reduce the rate of absorption of tetracyclines
may increase the CNS depressant effect of CNS depressants
may increase the hypoglycemic effect of sulfonylureas
may decrease the levels of serum concentration
may decrease the levels of serum concentration
may decrease the levels of serum concentration
may decrease the levels of serum concentration
may decrease the levels of serum concentration
may increase the CNS depressant effect of CNS Depressants
may decrease the rate of absorption
may decrease the rate of absorption
may decrease the rate of absorption
may decrease the rate of absorption
may decrease the rate of absorption
may decrease the rate of absorption
may decrease the rate of absorption
may decrease the rate of absorption
may diminish the absorption of magnesium salts
may diminish the absorption when combined with tetracyclines
may have a decrease in excretion when combined with minocycline
When both drugs are combined, there may be an increased effect of antithrombin alfa
When both drugs are combined, there may be an increased effect of antithrombin III
Tetracyclines work with cations to coordinate with OmpF and OmpC porins to enter bacterial cells.
Tetracyclines can enter the periplasm as a result, where they separate and the lipophilic tetracycline diffuses into the bacterial cytoplasm.
Tetracyclines decrease protein synthesis by blocking the binding of aminoacyl-tRNA to the 30S ribosome.
Adverse drug reactions:
Frequency Not Defined
Anaphylaxis
Angioneurotic edema
Eosinophilia
Pneumonitis
Nephritis
Myocarditis
Swelling of the face
Lymphadenopathy
Angioedema
Alopecia
Erythema nodosum
Erythematous rash
Exfoliative dermatitis
Pruritus
Toxic epidermal necrolysis
Urticaria
Dizziness
Fever
Fatigue
Somnolence
Angioedema
Thyroid dysfunction
Thyroid discoloration
Thyroid cancer
Vulvovaginitis
Pericarditis
Myocarditis
Vasculitis
Hemolytic anemia
Neutropenia
Thrombocytopenia
Pancytopenia
Hepatic cholestasis
Hepatitis
Hyperbilirubinemia
CNS effects
Clostridium difficile diarrhea
None
Contraindication:
Hypersensitivity
Caution:
Liver Toxicity
Central Nervous System (CNS) Effects
Photosensitivity
Intracranial Hypertension
Pregnancy warnings:
Breastfeeding warnings:
Pregnancy Categories:
Minocycline is a tetracycline antibiotic that inhibits protein synthesis by attaching itself to the bacterial 30S ribosomal subunit.
Patients should get counselling on the dangers of pseudotumor cerebri, central nervous system side effects, pseudomembranous colitis, and tooth and bone growth.
Avoid rapid intravenous infusion in IV administration and infuse over one hour.
Daily dose should not be more than 400 mg.
It is administered through oral route in form of tablet and capsule.
It should be taken with or without food.
Swallow tablets whole at time and avoid chewing or crush.
Patient Information Leaflet
Generic Name: minocycline (Rx)
Pronounced: min· o· cy· cline
Why do we use minocycline?
In people with periodontitis, subgingival microspheres are recommended as an adjuvant treatment to decrease pocket depth.
Oral and topical minocycline forms are used to treat inflammatory lesions of acne vulgaris.
Minocycline oral and intravenous formulations are indicated to treat infections of susceptible microorganisms.
Both our subscription plans include Free CME/CPD AMA PRA Category 1 credits.
On course completion, you will receive a full-sized presentation quality digital certificate.
A dynamic medical simulation platform designed to train healthcare professionals and students to effectively run code situations through an immersive hands-on experience in a live, interactive 3D environment.
When you have your licenses, certificates and CMEs in one place, it's easier to track your career growth. You can easily share these with hospitals as well, using your medtigo app.
